Benzinga · Oct 20, 2026
Kodiak Sciences Files Shelf Prospectus For Offering; Size Not Disclosed
-SEC Filing
KO
NASDAQ · KOD
Kodiak Sciences Inc.
Healthcare · Biotechnology
$99.18
Down-$1.22 (-1.22%)
Updated Nov 2, 2026, 10:26 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.28B
- P/E ratio
- -8.18
- Dividend yield
- 0.00%
- 52-week range
- $15.83 – $104.00
- Volume
- 568.1K
- Avg. volume
- 929.49K
Price performance · KOD
KOD price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
KOD closed at $99.18 after 20 trading sessions, up 5.72% for the selected period.
- Last close
- $99.18
- Period change
- +5.72%
- Period low
- $81.09
- Period high
- $100.40
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $99.41 | $100.6901 | $96.58 | $99.18 | 568.1K |
| Oct 29, 2026 | $96.07 | $103.7271 | $96.0019 | $100.40 | 1.17M |
| Oct 28, 2026 | $90.59 | $97.80 | $90.00 | $97.04 | 976.44K |
| Oct 27, 2026 | $89.65 | $94.73 | $89.20 | $91.32 | 1.01M |
| Oct 26, 2026 | $88.03 | $91.89 | $87.6075 | $89.60 | 927.03K |
| Oct 23, 2026 | $85.13 | $87.85 | $83.1567 | $87.63 | 526.95K |
| Oct 22, 2026 | $87.14 | $89.5199 | $84.86 | $85.78 | 593.7K |
| Oct 21, 2026 | $91.14 | $94.6427 | $87.29 | $87.72 | 943.27K |
| Oct 20, 2026 | $90.84 | $96.12 | $89.53 | $92.97 | 868.57K |
| Oct 19, 2026 | $86.84 | $92.74 | $86.50 | $91.35 | 1.05M |
| Oct 16, 2026 | $87.18 | $89.782 | $85.20 | $85.75 | 1.12M |
| Oct 15, 2026 | $81.30 | $88.50 | $79.06 | $88.12 | 1.4M |
| Oct 14, 2026 | $90.62 | $90.62 | $80.1422 | $81.09 | 2.41M |
| Oct 13, 2026 | $99.29 | $99.55 | $91.27 | $91.63 | 1.55M |
| Oct 12, 2026 | $100.08 | $103.2699 | $97.02 | $99.26 | 1.33M |
| Oct 9, 2026 | $94.97 | $100.33 | $93.70 | $99.87 | 1.74M |
| Oct 8, 2026 | $90.01 | $94.95 | $89.54 | $94.26 | 1.53M |
| Oct 7, 2026 | $91.74 | $94.25 | $89.91 | $91.08 | 1.31M |
| Oct 6, 2026 | $92.86 | $95.5439 | $89.70 | $92.34 | 1.48M |
| Oct 5, 2026 | $92.855 | $96.64 | $87.58 | $93.81 | 3.24M |
Latest KOD news
The latest Smart Investors Daily articles mentioning KOD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
KOD research
Overview
Company profile and research snapshot.
Company profile
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $17.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 28, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 28, 2026 | UBS | Buy | — |
| Sep 28, 2026 | LifeSci Capital | Outperform | — |
| Sep 24, 2026 | Goldman Sachs | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 19, 2026
Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?
Kodiak's Zenkuda shows promise across three retinal diseases, with positive phase III data and a planned 2026 regulatory filing.
Benzinga · Oct 12, 2026
HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $126
HC Wainwright & Co. analyst Matthew Caufield maintains Kodiak Sciences (NASDAQ:KOD) with a Buy and raises the price target from $96 to $126.
SeekingAlpha · Oct 10, 2026
Kodiak Sciences Inc. (KOD) Presents at American Academy of Ophthalmology Conference 2026 - Slideshow
2026-10-10. The following slide deck was published by Kodiak Sciences Inc.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
